Dyne Therapeutics Inc (Dyne Therapeutics) is a clinical-stage muscle disease company that develops innovative therapeutics for genetically driven diseases. The company develops drugs by using the FORCE platform. Its pipeline products include DYNE-101, which consists of a proprietary Fab conjugated to an antisense oligonucleotide (ASO) that treats myotonic dystrophy type 1 (DM1); DYNE-251, which consists of a phosphorodiamidate morpholino oligomer (PMO) conjugated to a proprietary Fab that treats Duchenne muscular dystrophy (DMD); DYNE-301 targets DUX4 that treats facioscapulohumeral muscular dystrophy (FSHD). The company also evaluating programs to treat rare skeletal, cardiac and metabolic muscle diseases. Dyne Therapeutics is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
1560 Trapelo Road, Waltham, Massachusetts, 02451
Website
dyne-tx.com
Telephone
1 781 7868230
No of Employees
141
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DYN (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-40.4%
(2022 vs 2021)
Market Cap*
$2.1B
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | FORCE |
| DYNE-101: Myotonic Dystrophy Type 1 | |
| DYNE-301: Facioscapulohumeral Muscular Dystrophy | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Product Approvals | In September, the company received approval for orphan drug designation from the U.S. Food and Drug Administration for DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1). |
| 2023 | Stock Listings/IPO | In September, The company’s shares were listed on the Nasdaq Global Select Market under the ticker symbol DYN. |
| 2022 | New Product Approvals | In July, the company received approval from the New Zealand Medicines and Medical Devices Safety Authority for a clinical trial application to start Phase 1/2 multiple ascending dose (MAD) clinical trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). |
Competitor Comparison
| Key Parameters | Dyne Therapeutics Inc | Pfizer Inc | Sanofi | Novo Nordisk AS | Vertex Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | Denmark | United States of America |
| City | Waltham | New York | Paris | Bagsvaerd | Boston |
| State/Province | Massachusetts | New York | Ile-de-France | - | Massachusetts |
| No. of Employees | 141 | 88,000 | 87,994 | 63,370 | 5,400 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jason Rhodes | Chairman | Executive Board | 2017 | 53 |
| John G. Cox | President; Chief Executive Officer | Senior Management | 2024 | - |
| Susanna High | Chief Operating Officer | Senior Management | 2020 | 55 |
| Wildon Farwell, M.D. | Chief Medical Officer | Senior Management | 2021 | 48 |
| Oxana Beskrovnaya, Ph.D. | Chief Scientific Officer | Senior Management | 2021 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer